

EliA™ APS: Identify antiphospholipid syndrome

Testing for APS associated antibodies according to classification criteria¹

- Determination of anti-cardiolipin IgG and IgM antibodies
- Determination of anti-β2-glycoprotein I IgG and IgM antibodies
- Use of consensus cut-off for anti-cardiolipin antibodies

High clinical relevance of EliA Cardiolipin IgG/M and EliA β2-Glycoprotein I IgG/M




Fig.1: EliA Cardiolipin IgG/M and EliA β2-Glycoprotein I IgG/M in various clinical cohorts (internal study)

The fully automated EliA APS tests provide objective and reliable diagnostic guidance. Their high sensitivity and excellent specificity for EliA APS assure high clinical values in different clinical settings². In addition, EliA APS tests can be run on all Phadia Laboratory Systems which maximize the flexibility and offer tailor-made solutions for various sizes of laboratories.

	EliA Cardiolipin IgG	EliA Cardiolipin IgM	EliA Cardiolipin IgA	EliA β2-Glycoprotein I IgG	EliA β2-Glycoprotein I IgM	EliA β2-Glycoprotein I IgA
Sensitivity (%)	43	30	7	59	24	44
Specificity (%)	99	92	99	96	96	96.5

Table 1: Clinical performance of EliA Cardiolipin/β2-glycoprotein I IgG, IgM and IgA. The data are extracted from an independent study² (with 100 APS patients and 129 disease controls).

EliA™ APS: Improved lab analysis and diagnostics

Test completely automated and efficient

Serum or plasma samples are processed automatically by Phadia Laboratory Systems (Phadia 100/200/250/2500/5000) by reducing the workload for your lab personnel. Operational costs are minimized and planning simplified—leading to an optimized workflow!

Your advantages with EliA Cardiolipin/EliA β 2-Glycoprotein I IgG, IgM and IgA*

- Excellent performance supporting the diagnosis of APS
- High level of standardization
- Completely automated and efficient testing
- Reducing workload for your lab personnel

* Isolated elevation of IgA anti-cardiolipin and anti- β 2-GPI antibodies can occur in APS patients³. The more markers / isotypes are found positive, the higher the probability for APS¹. Internal study shows that the test sensitivity and specificity of EliA Cardiolipin IgA are 21% and 98.5%, for EliA β 2-Glycoprotein I IgA are 44% and 96.5%, respectively.

EliA Cardiolipin/EliA β 2-Glycoprotein I IgG, IgM and IgA assist you to improve service quality: fully automated testing for specific markers for antiphospholipid syndrome.

Technical data

	EliA Cardiolipin IgG	EliA Cardiolipin IgM	EliA Cardiolipin IgA	EliA β 2-Glycoprotein I IgG	EliA β 2-Glycoprotein I IgM	EliA β 2-Glycoprotein I IgA
Antigen	bovine Cardiolipin, with bovine β 2GPI	bovine Cardiolipin, with bovine β 2GPI	bovine Cardiolipin, with bovine β 2GPI	purified human β 2-Glycoprotein I	purified human β 2-Glycoprotein I	purified human β 2-Glycoprotein I
Kit Size	4 x 12	4 x 12	2 x 12	4 x 12	4 x 12	2 x 12
Unit	GPL-U/ml	MPL-U/ml	APL-U/ml	U/ml	U/ml	U/ml
Negative	< 10	< 10	< 14	< 7	< 7	< 7
Equivocal	10–40 (weak positive)	10–40 (weak positive)	14–20	7–10	7–10	7–10
Positive	> 40	> 40	> 20	> 10	> 10	> 10
Dilution	1:10	1:10	1:10	1:10	1:50	1:10
Article No.	14-5529-01	14-5530-01	14-5528-01	14-5532-01	14-5533-01	14-5531-01

References

- 1 Miyakis, S. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4, 295–306, doi:10.1111/j.1538-7836.2006.01753.x (2006).
- 2 Fujieda, Y. et al. [Clinical significance of antiphospholipid antibody measured by EliA anticardiolipin antibodies and anti-beta2Glycoprotein I antibodies in antiphospholipid syndrome]. Nihon Rinsho Meneki Gakkai Kaishi 37, 430–436, doi:10.2177/jsci.37.430 (2014).
- 3 Lakos, G. et al. Isotype distribution and clinical relevance of anti-beta2-glycoprotein I (beta2-GPI) antibodies: importance of IgA isotype. Clin Exp Immunol 117, 574–579 (1999).

ThermoFisher
SCIENTIFIC

Distributed by Abacus dx

1800 ABACUS (AUS) 0800 222 170 (NZ) | info@abacusdx.com | www.abacusdx.com

abacus dx